Latest News
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
...
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
...
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
9 March 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patient...
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
9 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Monday reported positive topline results from a Phase 2 study evaluating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis.The trial met its primary endpo...
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD
9 March 2026 - Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystroph...